non injection glp 1 How GLP-1 medications are transforming diabetes and weight loss treatment How to Find a Health
Description
In a 48-week phase II clinical trial conducted on patients with type 2 diabetes and obesity, treatment with a dose of 10 mg/kg of bimagrumab resulted in a significant reduction in fat mass by 20.5% (compared to 0.5% in the placebo group), while lean body mass increased by 3.6% (as opposed to a decrease of 0.8% in the placebo group), leading to an overall body weight reduction of -6.5%, which was substantially better than the -0.8% observed in the placebo group
Do Incretins play a role in the remission of type 2 diabetes after gastric bypass surgery: What are the evidence
Diabetes 14 June 2024
All individuals were unique users and had not received any of the three medications prior
The effect of oral antidiabetic agents on A1C levels: a systematic review and meta-analysis
This is the only weight loss medication that works in the gut rather than the brain
